Breast Cancer Risk clinical trials

Explore recruiting breast cancer risk clinical trials.

Recruiting breast cancer risk studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Breast Cancer Risk trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Low dose TamOxifen and LifestylE changes for bReast cANcer prevenTion: a randomized phase II biomarker trial in subjects at increased risk (TOLERANT Study)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Breast Cancer Risk trials by city

Breast Cancer Risk in Toronto Breast Cancer Risk in Vancouver Breast Cancer Risk in Montreal Breast Cancer Risk in Calgary Breast Cancer Risk in Edmonton Breast Cancer Risk in Ottawa Breast Cancer Risk in Winnipeg Breast Cancer Risk in Quebec City Breast Cancer Risk in Hamilton Breast Cancer Risk in Kitchener Breast Cancer Risk in London Breast Cancer Risk in Halifax Breast Cancer Risk in New York Breast Cancer Risk in Los Angeles Breast Cancer Risk in Chicago Breast Cancer Risk in Houston

Breast Cancer Risk clinical trials

Recruiting breast cancer risk studies right now

Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy

A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Trial Evaluating Role of Post Mastectomy Radiotherapy in Women With Node Negative Early Breast Cancer

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Also recruiting in Europe

Low dose TamOxifen and LifestylE changes for bReast cANcer prevenTion: a randomized phase II biomarker trial in subjects at increased risk (TOLERANT Study)

Breast Cancer Risk trials by city

Other conditions